| Cat. No. | Product name | CAS No. |
| DCC4911 |
Sstr5a
Novel somatostatin receptor subtype 5 antagonist, stimulating glucoseinduced GLP-1 secretion, reducing blood glucose in a gut- and GLP-1R-dependent manner |
|
| DCC4912 |
St026567
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
5067-25-4 |
| DCC4913 |
St029248
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
96-69-5 |
| DCC4914 |
St056083
Novel inhibitor of the c-di-AMP synthetase DNA integrity scanning protein (DisA) in vitro |
299419-24-2 |
| DCC4915 |
St101036
Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
1018143-39-9 |
| DCC4916 |
st-1032
Novel histamine H3 receptor ligand |
|
| DCC4917 |
St1237
Potent, direct, non-cytotoxic Arachidonate_5-lipoxygenase>5-lipoxygenase (5-LO) inhibitor |
1380593-17-8 |
| DCC4918 |
St-161
Antiviral agent against LASV and a number of other viruses in the Arenaviridae family |
|
| DCC4919 |
St-1703
Novel histamine H3 receptor ligand |
|
| DCC4920 |
St-1892
Novel highly potent and soluble partial FXR agonist |
1409411-32-0 |
| DCC4921 |
St-198
Seletive dopamine D3 receptors |
854924-64-4 |
| DCC4922 |
St-1992
Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
| DCC4923 |
St-2001
Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
| DCC4924 |
St-2262
Novel selective NaV1.7 inhibitor, blocking the extracellular vestibule of the channel with an IC50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, NaV1.1-1.6 and NaV1.8 |
|
| DCC4925 |
St4070
Highly selective FAAH>fatty acid amide hydrolase (FAAH) inhibitor |
1186236-75-8 |
| DCC4926 |
St7710aa1
Novel PARP-1 inhibitor, showing significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp |
1542067-20-8 |
| DCC4927 |
Sta-9584
Novel tubulin-binding vascular disrupting agent (VDA) |
906481-23-0 |
| DCC4928 |
Stad-2
Cell permeable AKAP disruptor, selectively binding to PKA-RII and blocking the interaction of PKA-RI with AKAP |
1542100-77-5 |
| DCC4929 |
Stalobacin I
Novel Lipopeptide Antibiotic with Potent Antibacterial Activity against Multidrug-Resistant Bacteria |
|
| DCC4930 |
Stanozolol [10418-03-8]
Anabolic-androgenic steroid (AAS), acting as an agonist of the androgen receptor (AR) |
10418-03-8 |
| DCC4931 |
Stat3 -in-11
Novel STAT3 inhibitor, selectively inhibiting STAT3 phosphorylation and exhibiting potent antitumor activity |
|
| DCC4932 |
stat3 Inhibitor 6
Novel inhibitor of STAT3 signaling pathway |
665014-97-1 |
